Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal
À propos du CIUSSS
Accueil Plan du site Courrier Portail Québec
Size of text
AAA

Potvin, Stéphane

Ph. D. in biomedical sciences

Researcher, Institut universitaire en santé mentale de Montréal
Research Center

Associate professor, Department of Psychiatry, University of Montreal

Holder, Eli Lilly Chair in Schizophrenia Research

Phone: 514-251-4015
stephane.potvin@umontreal.ca

Research Areas of expertise

Schizophrenia,antipsychotic, pain, drug addiction, neuroimaging

 

Profile

Stéphane Potvin is working on the harmful role of cannabis and alcohol on brain structures in schizophrenia, focusing particularly on the brain's reward system. He is also interested in mechanisms of modulation of the affective components of pain and emotion processing in schizophrenia patients that are abusing cannabis by using neuroimaging techniques such as functional magnetic resonance imaging. He is holder of the Chair in Schizophrenia Research funded by Eli Lilly Canada, Institut universitaire en santé mentale de Montreal Foundation and the Hospital Sacré-Coeur de Montréal Foundation.

Grants and Awards

  • Syndrome métabolique et troubles du sommeil dans la schizophrénie: un projet pilote basé sur les données de la Banque signature (co-applicant, Institut universitaire en santé mentale de Montréal Foundation/Bell, 2015).
  • How are commorbidities in schizophrenia linked to release from hospital and social functionning ? (co-chercheur, Fondation de l'Institut universitaire en santé mentale de Montréal/Bell, 2015).
  • Eli Lilly Chair of Schizophrenia Research of the University of Montreal (Holder, 2014-2017).
  • Fondation de l'Institut universitaire en santé mentale de Montréal (salarial support, 2012-).
  • Schizophrénie et violence (co-chercheur, Fondation de l'Institut universitaire en santé mentale de Montréal, 2015-2018).
  • Electrophysiological and brain imaging of normal and abnormal pain modulatory systems (CIHR, Co-Applicant, 2008-2013).
  • Comorbidity in schizophrenia and drug addiction: Focus on the reward system (FRQS, Principal Investigator, 2009-2012).
  • Clinical and biological correlates of cannabis craving in schizophrenia and its treatment with rTMS (CIHR, Principal Investigator, 2010-2012).
  • The clinical and biological correlates of cannabis craving in schizophrenia  and its treatment with trans-cranial magnetic stimulation (CIHR, Principal Investigator, 2010-2011).
  • Scholarship award Junior 1 (Fonds de recherche en santé du Québec, 2009).

Publications

2016

Potvin, S., Aubin, G., & Stip, E. (2016). L'insight neurocognitif dans la schizophrénie. Encephale. Epub ahead of print. Pubmed

2015

Zhornitsky, S., Tikasz, A., Rizkallah, E., Chiasson, J. P., & Potvin, S. (2015). Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. J Addict, 2015, 843762. Pubmed

Potvin, S., Tikasz, A., Dinh-Williams, L. L., Bourque, J., & Mendrek, A. (2015). Cigarette Cravings, Impulsivity, and the Brain. Front Psychiatry, 6, 125. Pubmed

Mancini-Marie, A., Yoon, U., Jiminez, J., Fahim, C., Potvin, S., Grant, J. A., Laverdure-Dupont, D., Dube, A. A., Betrisey, C., Rainville, P., Evans, A. C., Stip, E., Mendrek, A. (2015). Sex, age, symptoms and illness duration and their relation with gyrification index in schizophrenia. Clin Schizophr Relat Psychoses. Epub ahead of print. Pubmed

Lungu, O., Potvin, S., Tikasz, A., & Mendrek, A. (2015). Sex differences in effective fronto-limbic connectivity during negative emotion processing. Psychoneuroendocrinology, 62, 180-188. Pubmed

Gougeon, V., Gaumond, I., Goffaux, P., Potvin, S., & Marchand, S. (2015). Triggering Descending Pain Inhibition by Observing Ourselves or a Loved-one in Pain. Clin J Pain. Epub ahead of print. Pubmed

Potvin, S., Zhornitsky, S., & Stip, E. (2015). Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can J Psychiatry, 60(3 Suppl 2), S26-34. Pubmed

Stip, E., & Potvin, S. (2015). The 10th anniversary of the eli lilly chair of schizophrenia from the university of montreal. Can J Psychiatry, 60(3 Suppl 2), S1-4. Pubmed

Potvin, S. (2015). Neuroimaging of cigarette cravings: individual differences matter: commentary. Addiction, 110(2), 204-205. Pubmed

Zhornitsky S, Stip E, Potvin S. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Canadian Journal of Psychiatry 2015; 60 (Suppl 2): S26-S34.

Stip E, Potvin S. Le 10ème anniversaire de la Chaire Eli Lilly de schizophrénie de l’Université de Montréal. Canadian Journal of Psychiatry 2015; 60 (Suppl 2): S1-S4.

2014

Boudjani, H., Potvin, S., Chayer, C., Charbonneau, S., & Lanthier, S. (2014). Striatum inhibition: clues for cocaine addiction therapy. Can J Neurol Sci, 41(5), 664-665. Pubmed

Potvin, S., Lungu, O. V., & Stip, E. (2014). Anandamide Is Involved in Appetite-Related Amygdala Hyperactivations in Schizophrenia Patients Treated With Olanzapine: A Functional Magnetic Resonance Imaging Study. J Clin Psychopharmacol. Epub ahead of print. Pubmed

Grot, S., Potvin, S., & Luck, D. (2014). Is there a binding deficit in working memory in patients with schizophrenia? A meta-analysis. Schizophr Res, 158(1-3), 142-145. Pubmed

Horn, M., Potvin, S., Allaire, J. F., Côté, G., Gobbi, G., Benkirane, K., Vachon, J., Dumais, A. (2014). Male inmate profiles and their biological correlates. Can J Psychiatry, 59(8), 441-449. Pubmed

Potvin, S., Stavro, K., Rizkallah, E., & Pelletier, J. (2014). Cocaine and Cognition: A Systematic Quantitative Review. J Addict Med. Epub ahead of print. Pubmed

Potvin, S., Aubin, G., & Stip, E. (2014). Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. Eur Arch Psychiatry Clin Neurosci. Epub ahead of print. Pubmed

Paquin, K., Wilson, A. L., Cellard, C., Lecomte, T., & Potvin, S. (2014). A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy learning? BMC Psychiatry, 14(1), 139. Epub ahead of print. Pubmed

Samaha, A. N., & Potvin, S. (2014). Drugs of abuse and psychiatric disorders: Neurobiological and clinical aspects. Prog Neuropsychopharmacol Biol Psychiatry. Epub ahead of print. Pubmed

2013

Dinh-Williams, L., Mendrek, A., Bourque, J., & Potvin, S. (2013). Where there's smoke, there's fire: The brain reactivity of chronic smokers when exposed to the negative value of smoking. Prog Neuropsychopharmacol Biol Psychiatry, 50C, 66-73. Pubmed

Oliere, S., Joliette-Riopel, A., Potvin, S., & Jutras-Aswad, D. (2013). Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction. Front Psychiatry, 4, 109. Pubmed

Tourjman, V., Kouassi, E., Koue, M. E., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., & Potvin, S. (2013). Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis. Schizophr Res. Epub ahead of print. Pubmed

Stavro, K., Pelletier, J., & Potvin, S. (2013). Widespread and sustained cognitive deficits in alcoholism: a meta-analysis. Addict Biol, 18(2), 203-213. Pubmed

Zhornitsky, S., Wee Yong, V., Koch, M. W., Mackie, A., Potvin, S., Patten, S. B., & Metz, L. M. (2013). Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair. CNS Neurosci Ther. Epub ahead of print. Pubmed

Bourque, J., Mendrek, A., Dinh-Williams, L., & Potvin, S. (2013). Neural circuitry of impulsivity in a cigarette craving paradigm. Front Psychiatry, 4, 67. Pubmed

Bourque, J., Mendrek, A., Durand, M., Lakis, N., Lipp, O., Stip, E., Lalonde, P., Grignon, S., Potvin, S. (2013). Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study. Psychiatry Res. Epub ahead of print. Pubmed

Potvin, S., Bourque, J., Durand, M., Lipp, O., Lalonde, P., Stip, E., Grignon, S., Mendrek, A. (2013). The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study. Schizophr Res Treatment, 2013, 543842. Pubmed

2012

Levesque, M., Potvin, S., Marchand, S., Stip, E., Grignon, S., Pierre, L., Lipp, O., Goffaux, P. (2012). Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile. Pain Medicine, 13(12), 1571-1579. Pubmed

Abdel-baki, A., Salvat, E.,  Ouellet-Plamondon, C., Potvin, S., Nicole, L. (2012). Impact of the course of substance use disorder on symptomatic and functional outcome in first-episode psychosis: A 2-year prospective study of patients in the Universite de Montreal's Network of Early Psychosis Intervention Programs (UMNEPIP). Early Intervention in Psychiatry 6:116-116.

Desfosses, J., Stip, E., Bentaleb, L. A., Lipp, O., Chiasson, J. P., Furtos, A., Venne, K., Kouassi, E., Potvin, S. (2012). Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Front Psychiatry 3: 85.  Pubmed

Ouellet-Plamondon, C., Abdel-Baki, A., Salvat, E., Potvin, S., Nicole, L. (2012). Does cannabis really influence first episode psychosis outcome negatively? Early Intervention in Psychiatry 6: 116-116.

Ouellet-Plamondon, C., Nicole, L., Salvat, E., Potvin, S., Abdel-Baki, A. (2012). Predictive factors of substance use disorders persistence 2 years after admission in first-episode psychosis (FEP) programs. Early Intervention in Psychiatry 6: 116-116.

Potvin, S., Larouche, A., Gaumond, I., Marchand, S., Grignon, S. (2012). Is Serotonin Involved in the Pathophysiology of Functional Chronic Pain? Biological Psychiatry 71(8): 169S-169S.

Potvin, S., Larouche, A., Gaumond, I., Marchand, S., Grignon, S. (2012). The Tumor Necrosis Factor-Alpha G308a Gene Polymorphism Influences Thermal Hyperalgesia in Patients with Functional Pain and Healthy Controls. Biological Psychiatry 71(8): 105S-105S.

Potvin, S., Mancini-Marie, A., Stip, B., Fahim, C.,  Stip, E. (2012). Decreased Grey Matter Volumes in Schizophrenia: A Voxel-based Morphometry Study Using Dartel Tools. Biological Psychiatry 71(8): 267S-267S.

Potvin, S., Morin, M., Cloutier, C., Gendron, A., Bissonnette, A., Marchand, S. (2012). Add-on Treatment of Quetiapine for Fibromyalgia: A Pilot, Randomized, Double-Blind, Placebo-Controlled 12-Week Trial. J Clin Psychopharmacol 32(5): 684-7.  Pubmed

Potvin, S., Paul-Savoie, E.,  Morin, M., Bourgault, P., Marchand, S. (2012). Temporal summation of pain is not amplified in a large proportion of fibromyalgia patients. Pain Res Treat    [Epub ahead of print]  Pubmed

Bourque, J.,  Durand, M., Lipp, O., Grignon, S., Mendrek, A., Potvin, S. (2012). The Neural Correlates of Positive Emotion Memory in Cannabis-Abusing Patients with Schizophrenia: Preliminary Fmri Results. Biological Psychiatry 71(8): 267S-267S.

Potvin, S., Desfosses, J., Venne, K., Furtos, A., Kouassi, E. (2012). Decreases in Plasma Endocannabinoid Levels Persist After Drug Withdrawal in Substance Abusers. Biological Psychiatry 71(8): 169S-169S.

Sadekova, N., S. Potvin, et al. (2012). "Interleukin-6 and Interleukin-1 Receptor Antagonist in Patients with Schizophrenia and/or Substance use Disorders: A Case-Control Study." Biological Psychiatry 71(8): 105S-105S.

Zhornitsky, S., Aubin, G., Desfosses, J., Rizkallah, E., Pampoulova, T., Lipp, O., Chiasson, J. P., Stip, E., Potvin, S. (2012). Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Ment Health J. [Epub ahead of print]  Pubmed

Zhornitsky, S., Rizkallah, E., Pampoulova, T., Chiasson, J. P., Lipp, O., Stip, E., Potvin, S. (2012). Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res, 200(2-3), 237-241.  Pubmed

Potvin, S., Stavro, K., Pelletier, J. (2012). Paradoxical cognitive capacities in dual diagnosis schizophrenia: The quest for explanatory factors. Journal of Dual Diagnosis 8(1): 35-47.

2011

Potvin, S.(2011). Experimental study of pain perception in major depressive disorder. Douleur Et Analgesie 24(3): 144-151.

Potvin, S. (2011). Pain insensitivity in schizophrenia. Douleur Et Analgesie 24(3): 152-159.

Chiasson, J. P., Stavro, K., Rizkallah, E., Lapierre, L., Dussault, M., Legault, L., Potvin, S. (2011). Questioning the Specificity of ASRS-v1.1 to Accurately Detect ADHD in Substance Abusing Populations. J Atten Disord. 16(8), 661-663. Pubmed

Dumais, A., Potvin, S., Joyal, C., Allaire, J. F., Stip, E., Lesage, A., Gobbi, G., Cote, G. (2011). Schizophrenia and serious violence: A clinical-profile analysis incorporating impulsivity and substance-use disorders. Schizophrenia research. 130 (1-3),234-237. Pubmed

Igue, R., Potvin, S., Bah, R., Stip, E., Bouchard, R. H., Lipp, O., Gendron, A. Kouassi, E. (2011). Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progress in neuro-psychopharmacology & biological psychiatry, 35(7), 1695-1698. Pubmed

Paul-Savoie, E., Potvin, S., Daigle, K., Normand, E., Corbin, J. F., Gagnon, R., Marchand, S. (2011). A Deficit in Peripheral Serotonin Levels in Major Depressive Disorder but not in Chronic Widespread Pain. The Clinical journal of pain, 27(6), 529-534.  Pubmed

Rizkallah, E., Belanger, M., Stavro, K., Dussault, M., Pampoulova, T., Chiasson, J. P., Potvin, S. (2011). Could the use of energy drinks induce manic or depressive relapse among abstinent substance use disorder patients with comorbid bipolar spectrum disorder? Bipolar Disord, 13(5-6), 578-580. Pubmed

Rizkallah, E., Legault, L., Pampoulova, T., Levesque, S., Belanger, M., Stavro, K., Chiasson, J. P., Potvin, S. (2011). A case report of concerta misuse in a patient with comorbid substance use disorder and attention deficit hyperactivity disorder. The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions, 20(5), 478-479. Pubmed

Zhornitsky, S., Potvin, S., Moteshafi, H., Dubreucq, S., Rompre, P. P., & Stip, E. (2011). Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. International clinical psychopharmacology, 26(4), 183-192. Pubmed

Zhornitsky, S., Potvin, S. P., Aubin, G., & Stip, E. (2011). Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophrenia. The Australian and New Zealand journal of psychiatry. Pubmed

Zhornitsky, S., Stip, E., Desfosses, J., Pampoulova, T., Rizkallah, E., Rompre, P. P., Bentaleb, L. A., Lipp, O., Chiasson, J. P., Gendron, A., Potvin, S. (2011). Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine. Frontiers in psychiatry / Frontiers Research Foundation, 2, 22. Pubmed

2010

Desfosses, J., Stip, E., Bentaleb, L. A., & Potvin, S. (2010). Endocannabinoids and schizophrenia. [Review]. Pharmaceuticals, 3 (10), 3101-3126.

Chiasson, J. P., Rizkallah, E., Stavro, K., Dussault, M., Pampoulova, T., Tourjman, V., Potvin, S. (2010). Is the Mood Disorder Questionnaire an appropriate screening tool in detecting bipolar spectrum disorder among substance use populations? The American journal of drug and alcohol abuse. Pubmed

Normand, E., Potvin, S., Gaumond, I., Cloutier, G., Corbin, J. F., & Marchand, S. (2010). Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. The Journal of clinical psychiatry. Epub ahead of print. Pubmed

Zhornitsky, S., Potvin, S., Stip, E., & Rompre, P.-P. (2010). Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of D-amphetamine. European Neuropsychopharmacology Vol, 20(10), 695-703. Pubmed

Stip, E., Zhornitsky, S., Potvin, S., & Tourjman, V. (2010). Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies. Progress in neuro-psychopharmacology & biological psychiatry, 34(6), 997-1000.  Pubmed

Zhornitsky, S., Rizkallah, E., Pampoulova, T., Chiasson, J. P., Stip, E., Rompre, P. P., Potvin, S., et al. (2010). Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. Journal of clinical psychopharmacology, 30(4), 417-424. Pubmed

Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., Chiasson, J. P., Potvin, S., (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement disorders : official journal of the Movement Disorder Society, 25(13), 2188-2194. Pubmed

Potvin S, Normand E, Corbin JF, (2011) Marchand S. Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. Journal of Clinical Psychiatry, 72(2): 219–224.

2009

Potvin S. Neuroimaging studies of substance abuse in schizophrenia. Current Psychiatry Reviews 2009; 5 (4): 250-60.

Potvin S, Blanchet P, Stip E. Substance abuse enhances extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophrenia Research 2009; 113 (2-3): 181-188.

Goffaux P, Barcellos-de-Souza J, Potvin S, Marchand S. Pain relief through expectation supersedes descending inhibititory deficits in fibromyalgia patients. Pain 2009; 145 (1-2): 18-23.

Larouche A, Potvin S, Normand E, Barcellos de Souza J, Grignon S, Marchand S. The DRD3 Ser9Gly polymorphism is related to thermal pain in chronic widespread pain patients and healthy volunteers. Journal of Pain 2009; 10 (9): 969-75.

De Souza JB, Goffaux P, Julien N, Potvin S, Charest J, Marchand S. Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Questionnaire: a preliminary study. Rheumatology International 2009; 29 (5): 509-15.

Potvin S, Grignon S, Marchand S. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009; 63 (5): 390-402.

De Souza JB, Potvin S, Goffaux P, Charest J, Marchand S. The deficit in pain inhibition is more pronounced in chronic widespread pain patients with comorbid depressive symptoms. Clinical Journal of Pain 2009; 25 (2): 123-7.

2008

Stip E, Mancini-Marië A, Fahim C, Bentaleb LA, Létourneau G, Potvin S. Decrease in basal ganglia grey matter density associated with atypical antipsychotic treatment. Schizophrenia Research 2008; 103 (1-3): 319-21.

Potvin S, Stip E, Lipp O, Tempier A, Bentaleb AL, Lalonde P, Goffaux P, Marchand S. (2008) Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization to thermal pain in schizophrenia. Journal Psychiatric Research 42: 1010-6.

Potvin S, Marchand S. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a meta-analysis. Pain 2008; 138 (1): 70-8.

Potvin S, Stip E, Kouassi E, Lipp O, Roy MA, Demers MF, Bouchard RH, Arista G, Piomelli D, Gendron A. (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology 22 (3): 262-9.

Potvin S, Lipp O, Pampoulova T, Bentaleb AL, Lalonde P, Stip E. Working memory in patients with schizophrenia and substance use disorders. Cognitive Neuropsychiatry 2008; 13 (4): 357-66.

Redmond WJ, Goffaux P, Potvin S, Marchand S. Anti-hyperalgesic properties of nabilone – evidence of a sex-difference. Current Medical Research and Opinion 2008; 24 (4): 1017-24.

Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities in substance-abusing schizophrenia patients: a meta-analysis. Schizophrenia Research 2008; 100: 242-51.

Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alteration in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008; 63 (8): 801-8.

Potvin S, Stip E, Lipp O, Roy MA, Demers MF, Bouchard RH, Gendron A. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. American Journal of Drug and Alcohol Abuse 2008; 34 (1): 75-82.

Potvin S, Ben Amar M. Cannabis use increases the risk of psychotic outcomes (commentary). Evidence-Based Mental Health 2008; 11: 28.

2007

Potvin S, Sepehry AA, Stip E. A meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Australian and New Journal of Psychiatry 2007; 41 (10): 792-9.

Potvin S, Mancini-Marïe A, Fahim C, Lévesque J, Karama S, Mensour B, Beauregard M, Rompré PP, Stip E. Increased striatal grey matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Research: Neuroimaging 2007; 154 (3): 275-9.

Potvin S, Mancini-Marië A, Fahim C, Mensour B, Stip E. A functional magnetic resonance imaging study of social emotion in schizophrenia patients with and without comorbid substance use disorder. Social Neuroscience 2007; 2 (2): 1-11.

Potvin S, Sepehry AA, Stip E. Comorbid substance-use in schizophrenia: the file drawer effect. Schizophrenia Research 2007; 90 (1-3): 351-2.

Sepehry AA, Potvin S, Élie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 2007; 68 (4): 604-10.

Ben Amar M, Potvin S. Cannabis and psychosis: what is the link? Journal of Psychoactive Drugs 2007; 39 (2): 131-42.

Levaux MN, Potvin S, Sepehry AA, Sablier J, Mendrek A, Stip E. Cognitive assessment in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry 2007; 22 (2): 104-15.

Fahim C, Stip E, Mancini-Marië A, Potvin S, Malaspina D. Orbitofrontal dysfunctioning in a monozygotic twin discordant for post-partum affective psychosis: a fMRI case study. Bipolar Disorders 2007; 9 (5): 541-5.

Potvin S, Stip E. Schizophrénie et toxicomanie: l’héritage du psychiatre Jean-Yves Roy. Santé Mentale au Québec 2007; 31 (2): 177-88.

Légaré N, Potvin S, Mancini-Marië A, Barabé P, Lipp O, Bouchard RH, Stip E. Améliorer les symptômes et le tabagisme chez les personnes souffrant de schizophrénie : un manque d’effet synergique du médicament antipsychotique. Santé Mentale au Québec 2007; 31 (2): 165-74.

Potvin S, Grignon S. Dopamine et douleur: une revue de littérature. Douleur & Analgésie 2007; 20 (4): 246-56.

Arsenault P, Potvin S. Le traitement pharmacologique de la fibromyalgie: par où commencer? Douleur & Analgésie 2007 ; 20 (4): 227-33.

2006

Potvin S, Stip E, Lipp O, Mancini-Marië A, Élie R, Roy MA, Rompré PP, Bouchard RH, Gendron A. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorder: an open-label trial. Current Medical Research Opinion 2006; 22 (7): 1277-85.

Mancini-Marië A, Potvin S, Fahim C, Mensour B, Beauregard M, Roy JY, Stip E. Neural correlates of the affect regulation model in schizophrenia patients with a substance use history: a functional magnetic resonance imaging study. Journal of Clinical Psychiatry 2006; 67 (3): 342-50.

Potvin S, Pampoulova T, Mancini-Marië A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in schizophrenia patients with a comorbid substance use disorder. Journal of Neurology, Neurosurgery & Psychiatry 2006; 77 (6): 796-8.

Potvin S, Sepehry AA, Stip E. Negative symptoms in dual diagnosis schizophrenia: a meta-analysis. Psychological Medicine 2006; 36 (4): 431-40.

Potvin S, Briand C, Prouteau A, Bouchard RH, Lipp O, Lalonde P, Nicole L, Lesage A, Stip E. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain & Cognition 2005; 59: 38-42.

Mancini-Marië A, Fahim C, Potvin S, Stip E. Quetiapine: focus on emotional blunting in depersonalization disorder: a fMRI case report. European Psychiatry 2006; 21 (8): 574-7.

2005

Tranulis C, Potvin S, Gourgue M, Leblanc G, Mancini-Marië A, Stip E. The paradox of quetiapine in obsessive-compulsive disorder. CNS Spectrums 2005; 10 (5): 356-61.

Potvin S, Stip E, Roy JY. Toxic psychoses as pharmacological models of schizophrenia. Current Psychiatry Reviews 2005; 1 (1): 23-32.

2004

Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in eight psychosis patients with drug dependency. Canadian Journal of Psychiatry 2004; 49 (10): 711.

2003

Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. International Clinical Psychopharmacology 2003; 18 (3):121-32.

Potvin S, Stip E, Roy JY. Schizophrenia and addiction: an evaluation of the self-medication hypothesis (french). L’Encéphale 2003 ; XXIX : 193-203.

Chapitres

Potvin S, Bauco P, Mancini-Marië A, Roy JY, Rompré PP. (2005) La toxicomanie: aspects fondamentaux et cliniques. Dans: Marquard-Botez T (éd.) Neuropsychologie Clinique et Neurologie du Comportement -3ème édition. Presses de l’Université de Montréal; pp. 635-645.

Potvin S, Stip E, Roy JY. (2005) Hedonic dysfunctions in schizophrenia: l’ennui à la folie. Dans: Lang MV (ed.) Trends in Schizophrenia Research. New York: Nova Science Publishers; pp. 119-149.

Potvin S, Stip E, Roy JY. Schizophrénie et cannabinoïdes: données cliniques, expérimentales et biologiques. Drogues, Santé & Société 2004; 2 (2): 61-97.

Potvin S, Benzaliouad F, Rompré PP. La toxicomanie: les drogues d’abus. Dans: Beaulieu P (éd.) Précis de Pharmacologie. Montréal: Presses de l’Université de Montréal. 2009.

Potvin S, Mancini-Marïe A, Fahim C, Stip E. Les anomalies de la matière grise et la matière blanche dans la schizophrénie: une approche confirmatoire. Dans: Stip É (éd.) ACFAS. Sur invitation.